Brokerages predict that Viking Therapeutics, Inc. (NASDAQ:VKTX) will report earnings of ($0.17) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Viking Therapeutics’ earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.17). Viking Therapeutics reported earnings of ($0.22) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 22.7%. The business is scheduled to issue its next earnings report on Wednesday, August 9th.

According to Zacks, analysts expect that Viking Therapeutics will report full-year earnings of ($0.69) per share for the current fiscal year, with EPS estimates ranging from ($0.70) to ($0.68). For the next year, analysts expect that the firm will post earnings of ($0.61) per share, with EPS estimates ranging from ($0.63) to ($0.59). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Viking Therapeutics.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Tuesday, March 21st. The biotechnology company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.02.

VKTX has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Viking Therapeutics in a research note on Monday, March 27th. Maxim Group set a $5.00 target price on shares of Viking Therapeutics and gave the company a “buy” rating in a research note on Wednesday, March 22nd.

A number of hedge funds have recently added to or reduced their stakes in VKTX. Renaissance Technologies LLC raised its stake in Viking Therapeutics by 62.9% in the first quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock valued at $388,000 after buying an additional 102,600 shares during the last quarter. Vanguard Group Inc. raised its stake in Viking Therapeutics by 22.4% in the first quarter. Vanguard Group Inc. now owns 330,689 shares of the biotechnology company’s stock valued at $483,000 after buying an additional 60,467 shares during the last quarter. Finally, GRT Capital Partners L.L.C. raised its stake in Viking Therapeutics by 187.8% in the fourth quarter. GRT Capital Partners L.L.C. now owns 94,978 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 61,978 shares during the last quarter. Hedge funds and other institutional investors own 3.22% of the company’s stock.

Viking Therapeutics (NASDAQ VKTX) opened at 1.26 on Tuesday. Viking Therapeutics has a 52-week low of $0.90 and a 52-week high of $1.70. The company has a 50 day moving average of $1.30 and a 200-day moving average of $1.32. The stock’s market capitalization is $30.15 million.

ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Anticipate Viking Therapeutics, Inc. (VKTX) Will Announce Earnings of -$0.17 Per Share” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/06/13/zacks-brokerages-anticipate-viking-therapeutics-inc-vktx-will-announce-earnings-of-0-17-per-share.html.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.